-+ 0.00%
-+ 0.00%
-+ 0.00%
Medtronic wins FDA clearance for Affera Prism-2 cardiac mapping software
Share
Listen to the news
Medtronic wins FDA clearance for Affera Prism-2 cardiac mapping software
  • Medtronic won FDA clearance and CE Mark for its Affera Prism-2 Mapping Software for use in cardiac ablation procedures.
  • CE Mark also granted for the PulseSelect ProxBox Adapter with Proximity Indicator software, adding real-time tissue proximity feedback.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief via PR Newswire (Ref. ID: CG59974) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending